RxDoctor Payments Data

William Koonce, MD

Internal Medicine · Santa Barbara, CANPI 1124010095

Payments from drug & device makers

$7,679in general payments, 2019–2025

Across 389 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Pfizer$842
  • AstraZeneca$552
  • Gilead$495
  • AbbVie$428
  • Tanabe Pharma America, Inc.$415
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$7,62499%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,679 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$507,942
Medicare patients
571
Services billed
7,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$162,455
XareltoRivaroxaban154$91,941
BiktarvyBictegrav/Emtricit/Tenofov Ala18$69,450
CreonLipase/Protease/Amylase18$65,967
FarxigaDapagliflozin Propanediol51$47,846
MyrbetriqMirabegron89$39,272
OzempicSemaglutide37$34,615
JardianceEmpagliflozin54$31,458
JanuviaSitagliptin Phosphate36$26,053
VascepaIcosapent Ethyl54$24,956
VraylarCariprazine Hcl11$16,000
EntrestoSacubitril/Valsartan14$11,430
ValtrexValacyclovir Hcl12$9,678
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$8,169
Icosapent Ethyl25$7,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$842$169,033290 claims
Johnson & JohnsonXarelto$411$91,941154 claims
AbbVieCreon, Vraylar, Synthroid$428$84,29590 claims
GileadBiktarvy$495$69,45018 claims
AstraZenecaFarxiga, Brilinta$552$53,96864 claims
Astellas Pharma US IncMyrbetriq$71$39,27289 claims
Novo NordiskOzempic$89$34,61537 claims
Boehringer IngelheimJardiance$300$31,45854 claims
MerckJanuvia$97$26,05336 claims
NovartisEntresto$221$11,43014 claims
Eisai Inc.Dayvigo$176$4,20612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →